| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/21/2008 | WO2008051523A3 Carbazole derivatives useful as medicaments in cancer therapy |
| 08/21/2008 | WO2008034736A3 Oxindole derivatives as anticancer agents |
| 08/21/2008 | WO2008024978A3 Tetrahydroindolone and tetrahydroindazolone derivatives |
| 08/21/2008 | WO2007146425A3 Compounds and methods for treatment of chemotherapy-induced anemia |
| 08/21/2008 | WO2007072022A3 Composition comprising an antigen-recognizing molecule and a lipid-based carrier |
| 08/21/2008 | US20080200674 Anticoagulants; cardiovascular disorders; atherosclerosis; antiarthritic agents;Alzheimer's disease; anticancer agents |
| 08/21/2008 | US20080200553 N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability |
| 08/21/2008 | US20080200552 side effect reduction; bone disease and psoriasis; compounds display the desirable cell differentiation and antiproliferative effects with reduced calcium mobilization; 2-(4-{1-Ethyl-1-[4-(1-hydroxy-cyclopentylethynyl)-3-methyl-phenyl]-propyl}-2-methyl-benzoylamino)-2-methyl-propionic acid |
| 08/21/2008 | US20080200543 side effects reduction; nontoxic; AIDS, a sepsis, anticancer agent; 1-oleoyl-2-2palmitoyl-3-acetylglycerol(R1/R2=9-octadecenoyl/hexadecanoyl; immune enhancing agent |
| 08/21/2008 | US20080200537 Administering extract from soy plants grown under stressed conditions; inhibiting selective estrogen receptor modulator induced uterotrophic effects |
| 08/21/2008 | US20080200523 Derivatives of squaric acid with anti-proliferative activity |
| 08/21/2008 | US20080200511 Novel Compounds and Methods of Using the Same |
| 08/21/2008 | US20080200509 Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth |
| 08/21/2008 | US20080200507 Water and organic solvent free crystal lattice; hydrophobic, water soluble; endometriosis and/or uterine leiomyoma; commercial scale; X ray diffraction pattern having peaks at 13.0, 13.6, 18.6, 19.0, 21.0 and 22.3 degrees |
| 08/21/2008 | US20080200504 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide |
| 08/21/2008 | US20080200494 Imidazopyridine Derivatives |
| 08/21/2008 | US20080200490 Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists |
| 08/21/2008 | US20080200489 Combination of Organic Compounds |
| 08/21/2008 | US20080200488 Combination comprising at least one pyrimidylaminobenzamide compound and an HSP90 inhibitor such as 17-allylamino-17-demethoxygeldanamycin has a beneficial effect in treatment of proliferative diseases, e.g., tumors, myelomas, leukemias, psoriasis, restenosis, sclerodermitis and fibrosis |
| 08/21/2008 | US20080200485 of Aurora-2 (Aurora-A) protein kinase; anticancer; 6-(pyrazolylamino)-4-pyrimidine carboxamides; Methyl 2-(4-cyclopropanecarboxamidophenylsulfanyl)-5-amino-6-(5-methylpyrazol-3-ylamino)-4-pyrimidinecarboxylate |
| 08/21/2008 | US20080200478 1,7-Bis-(2,6,6-trimethylcyclohex-1-en-1-yl)-1 (E)-heptadiene-3,5-dione, analogs and derivatives thereof for treating cancer; potent inhibitory effect on the proliferation of human promyelocyte leukemia HL-60 cells |
| 08/21/2008 | US20080200469 Phthalazinone derivatives |
| 08/21/2008 | US20080200464 Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide |
| 08/21/2008 | US20080200462 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 08/21/2008 | US20080200456 Adenosine A2B receptor antagonists; asthma, allergies, allergic diseases or an autoimmune disease, diarrheal diseases, insulin resistance, diabetes, cancer, ischemia, reperfusion injuries, retinopathy; e.g. 1,3-Dipropyl-8-(6-chloro-3-pyridyl)xanthine |
| 08/21/2008 | US20080200454 Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| 08/21/2008 | US20080200451 Antitumor agents; use in combination with other drugs such as pentamidine |
| 08/21/2008 | US20080200440 Progesterone receptor antagonists |
| 08/21/2008 | US20080200437 Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases |
| 08/21/2008 | US20080200433 Molecular Chaperone Function Regulator |
| 08/21/2008 | US20080200428 Antiproliferative Drug |
| 08/21/2008 | US20080200424 Preparation for Treating Cancer |
| 08/21/2008 | US20080200423 Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents |
| 08/21/2008 | US20080200420 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes |
| 08/21/2008 | US20080200405 Drug Resistance Reversal In Neoplastic Disease |
| 08/21/2008 | US20080200402 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones |
| 08/21/2008 | US20080200398 Compounds For Enzyme Inhibition |
| 08/21/2008 | US20080200393 Treat disease associated with substrate-phosphorylation by VEGF receptor, substrate-phosphorylation by PDGF receptor or substrate-phosphorylation by both VEGF and PDGF receptors |
| 08/21/2008 | US20080200391 Stimulating differentiation in growth of osteoblasts and osteoclasts; wound healing of bone fractures and de novo bone formation; osteoporosis; bone cancer treatment; polynucleotide encoding polypeptide; genetic engineering |
| 08/21/2008 | US20080200387 Anti-angiogenic protein, composition and use thereof |
| 08/21/2008 | US20080200377 Polyamideesters comprised of dicarboxylic acid and reaction product of diol and amino acid; drug delivery through blood vessels; controlled release, reduced adverse effects, inactivation protection, intracellular penetration enhanced pharmacological activity |
| 08/21/2008 | US20080200376 Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction |
| 08/21/2008 | US20080199917 Using vector comprising early gene modifications as genetic transfer element in gene therapy; gnentic vaccines |
| 08/21/2008 | US20080199885 Using tumor marker (mammaglobin B) profile as diagnostic/prognostic indicator for urogenital cancers in women |
| 08/21/2008 | US20080199865 Using allelic variation in interleukin-1RN variable number of tandem repeats as diagnostic/prognostic indicator of decrease cell division and aging characteristics |
| 08/21/2008 | US20080199864 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses |
| 08/21/2008 | US20080199550 Novel Anticancer Agent, Methods for Obtaining the Same and Pharmaceutical Compositions Thereof |
| 08/21/2008 | US20080199532 Congestive heart failure; induce vasodilation |
| 08/21/2008 | US20080199523 Particles Comprising A Releasable Dopant Therein |
| 08/21/2008 | US20080199515 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
| 08/21/2008 | US20080199491 vaccine containing antigen and non-liquid adjuvants ; implantable pellet, capsule, tablet, powder or aerosol |
| 08/21/2008 | US20080199486 Grp94-based compositions and methods of use thereof |
| 08/21/2008 | US20080199484 Using cyclooxgenase inhibitor as antitumor therapeutic in treatment of cell proliferative disorders |
| 08/21/2008 | US20080199482 Method For Inhibiting The Transendothelial Migration Of Cells Such As Leukocytes Or Tumor Cells By A Cd-Binding Substance And Uses Thereof |
| 08/21/2008 | US20080199472 Using secretory leukocyte protease inhibitor (SLPI) to identify modulators for treatment and prevention of tumor migration |
| 08/21/2008 | US20080199464 Combination Therapy with Angiogenesis Inhibitors |
| 08/21/2008 | US20080199463 Method for treating multiple myeloma |
| 08/21/2008 | US20080199459 Mitotic Kinesin Inhibitors |
| 08/21/2008 | US20080199454 Caspase inhibitor prodrugs |
| 08/21/2008 | US20080199438 Methods For Suppressing Tumor Proliferation |
| 08/21/2008 | US20080199435 IL-8 Like Protein |
| 08/21/2008 | US20080199425 Administering monophenol or benzenediol compounds which modify tyrosinase proteins; stimulate inflammatory response; 4-tertiary butylphenol, fludarabine and cyclophosphamide |
| 08/21/2008 | US20080199423 Enhancing apoptosis or cytolytic activity using natural killer cells;ligand polypeptide; interleukins, interferons; anticarcinogen |
| 08/21/2008 | DE102007008484A1 Pharmazeutische Zubereitung zur Bekämpfung von Metastasen Pharmaceutical composition for controlling metastases |
| 08/21/2008 | DE102005005397B4 Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms Isolation of N-butyl benzene, synthesis of benzenesulfonamide derivatives as well as using N-butyl benzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostatic hyperplasia and / or prostate carcinoma |
| 08/21/2008 | CA2728541A1 Crystalline forms of thiazolidinedione compound and its manufacturing method |
| 08/21/2008 | CA2678432A1 Vaccine therapy for choroidal neovascularization |
| 08/21/2008 | CA2678427A1 Dual acting prodrugs |
| 08/21/2008 | CA2678363A1 Drug resistance reversal in neoplastic disease |
| 08/21/2008 | CA2678181A1 Antibodies against erbb3 and uses thereof |
| 08/21/2008 | CA2678127A1 Tgf-beta stimulant and further agent to reduce side effects |
| 08/21/2008 | CA2677978A1 Salts forms of 4-phenylamino quinazoline derivative |
| 08/21/2008 | CA2677703A1 Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor |
| 08/21/2008 | CA2677651A1 Combinations of therapeutic agents for treating cancer |
| 08/21/2008 | CA2677621A1 Novel antibodies |
| 08/21/2008 | CA2677605A1 Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| 08/21/2008 | CA2677269A1 Anhydrous crystalline vinflunine salts, method of preparation and use thereof as a drug and means of vinflunine purification |
| 08/21/2008 | CA2676766A1 Anti-robo4 antibodies and uses therefor |
| 08/21/2008 | CA2673534A1 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular ikk inhibitors |
| 08/21/2008 | CA2673532A1 New phenyl-(4-phenyl-pyrimidin-2-yl)-amines derivatives, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors |
| 08/21/2008 | CA2672959A1 New n, n'- 2,4-dianilinopyrimidine derivatives, preparation thereof as drugs, pharmaceutical compositions essentially as ikk inhibitors |
| 08/21/2008 | CA2672955A1 New 2, 4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors |
| 08/21/2008 | CA2661853A1 Monoclonal antibody directed against the human ldl receptor |
| 08/20/2008 | EP1959013A1 Human circulating virus inhibitory peptide (VRIP) and its use |
| 08/20/2008 | EP1958951A1 Phosphine transition metal complex, method for producing same and antitumor agent containing same |
| 08/20/2008 | EP1958647A1 Pharmaceutical composition with bacteria for tumor treatment |
| 08/20/2008 | EP1958642A1 Regulation of cell growth by MUC1 |
| 08/20/2008 | EP1958641A1 Treatment and prevention of inflammation |
| 08/20/2008 | EP1958629A1 A transdermal fluid comprising tocotrienol |
| 08/20/2008 | EP1958503A2 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 08/20/2008 | EP1957647A2 Immunostimulatory oligoribonucleotides |
| 08/20/2008 | EP1957646A1 Compositions and methods for therapy and diagnosis of cancer |
| 08/20/2008 | EP1957539A2 Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use |
| 08/20/2008 | EP1957499A1 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| 08/20/2008 | EP1957498A2 Inhibitors of vegf receptor and hgf receptor signaling |
| 08/20/2008 | EP1957496A2 Bicyclic protein kinase inhibitors |
| 08/20/2008 | EP1957487A1 Novel pyridopyrazines and their use as modulators of kinases |
| 08/20/2008 | EP1957485A2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| 08/20/2008 | EP1957477A1 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| 08/20/2008 | EP1957476A1 L-alanine derivatives |